BG103729A - Нови производни на карбоксилни киселини, тяхното получаване и използването им за лечение на рак - Google Patents

Нови производни на карбоксилни киселини, тяхното получаване и използването им за лечение на рак

Info

Publication number
BG103729A
BG103729A BG103729A BG10372999A BG103729A BG 103729 A BG103729 A BG 103729A BG 103729 A BG103729 A BG 103729A BG 10372999 A BG10372999 A BG 10372999A BG 103729 A BG103729 A BG 103729A
Authority
BG
Bulgaria
Prior art keywords
cancer treatment
administration
preparation
carboxylic acids
new derivatives
Prior art date
Application number
BG103729A
Other languages
English (en)
Inventor
Cynthia ROMERDAHN
Original Assignee
Basf Aktiengesellschaft
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Basf Aktiengesellschaft filed Critical Basf Aktiengesellschaft
Publication of BG103729A publication Critical patent/BG103729A/bg

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Steroid Compounds (AREA)

Abstract

Изобретението се отнася до метод за лечение на рак, по-специално на тумори, в които ендотелиумът е с нарушена регулация, например тумор на простатата, белия дроб, черния дроб, млечната жлеза, мозъка,стомаха, дебелото черво, ендометриума, тестисите, тироидната жлеза, хипофизата, пикочния мехур, бъбреците, панкреаса и менингите. Методът се осъществява, като на пациента се дава ефективно количествоот съединение с формула I или Iа, посочени в описанието.
BG103729A 1997-03-14 1999-09-13 Нови производни на карбоксилни киселини, тяхното получаване и използването им за лечение на рак BG103729A (bg)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/818,622 US6030975A (en) 1997-03-14 1997-03-14 Carboxylic acid derivatives, their preparation and use in treating cancer
PCT/US1998/004596 WO1998041206A1 (en) 1997-03-14 1998-03-09 Novel carboxylic acid derivatives, their preparation and use in treating cancer

Publications (1)

Publication Number Publication Date
BG103729A true BG103729A (bg) 2000-04-28

Family

ID=25225984

Family Applications (1)

Application Number Title Priority Date Filing Date
BG103729A BG103729A (bg) 1997-03-14 1999-09-13 Нови производни на карбоксилни киселини, тяхното получаване и използването им за лечение на рак

Country Status (19)

Country Link
US (1) US6030975A (bg)
EP (1) EP0969841A1 (bg)
JP (1) JP2001517220A (bg)
KR (1) KR20000076252A (bg)
CN (1) CN1251991A (bg)
AU (2) AU734696B2 (bg)
BG (1) BG103729A (bg)
BR (1) BR9808263A (bg)
CA (1) CA2283732A1 (bg)
HR (1) HRP980126A2 (bg)
HU (1) HUP0002249A3 (bg)
ID (1) ID24283A (bg)
IL (1) IL131666A0 (bg)
NO (1) NO994426L (bg)
NZ (1) NZ337557A (bg)
PL (1) PL335688A1 (bg)
SK (1) SK125299A3 (bg)
WO (1) WO1998041206A1 (bg)
ZA (1) ZA982136B (bg)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19533023B4 (de) * 1994-10-14 2007-05-16 Basf Ag Neue Carbonsäurederivate, ihre Herstellung und Verwendung
DE19850301A1 (de) * 1998-10-30 2000-05-04 Basf Ag Verfahren zur Racematspaltung von 2-Hydroxypropionsäuren
US7566452B1 (en) 1999-05-04 2009-07-28 New York University Cancer treatment with endothelin receptor antagonists
US6545048B1 (en) * 1999-06-29 2003-04-08 California Institute Of Technology Compositions and methods of treating cancer using compositions comprising an inhibitor or endothelin receptor activity
CN1434715A (zh) * 2000-02-16 2003-08-06 山之内制药株式会社 药物组合物
WO2002064573A1 (de) * 2001-02-14 2002-08-22 Abbott Gmbh & Co. Kg Neue carbonsäurederivate mit alkylsubstituierten triazinen, ihre herstellung und verwendung als endothelin-rezeptorantagonisten
CN1568999A (zh) * 2003-07-14 2005-01-26 南宁枫叶药业有限公司 稳定的医药用河豚毒素冷冻干燥制剂
EP2118073A2 (en) 2007-02-02 2009-11-18 Concert Pharmaceuticals Inc. Selective endothelin type-a antagonists
WO2011071947A2 (en) 2009-12-07 2011-06-16 Johns Hopkins University Bis-acylated hydroxylamine derivatives
CN102276536B (zh) * 2011-06-10 2015-04-29 中国科学院化学研究所 一种光学纯的(+)-安倍生坦和光学纯的(+)-达芦生坦的制备方法
CN103709106A (zh) * 2013-12-06 2014-04-09 石家庄博策生物科技有限公司 一种立体选择性制备安立生坦的方法

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5382569A (en) * 1991-05-16 1995-01-17 Warner-Lambert Company Endotherlin antagonists
CA2072390A1 (en) * 1991-07-01 1993-01-02 Philip D. Stein Endothelin analogues with alpha-amine substitution at residue 20
CA2072395A1 (en) * 1991-07-01 1993-01-02 John T. Hunt Bicyclic endothelin analogues
EP0670737A4 (en) * 1992-03-26 1996-05-29 Gensia Inc IN VIVO PEPTIDE THERAPY.
US5550110A (en) * 1992-04-22 1996-08-27 Warner-Lambert Company Endothelin Antagonists II
CA2133090A1 (en) * 1992-04-22 1993-10-28 Wayne L. Cody Endothelin antagonists ii
WO1994003483A1 (en) * 1992-07-30 1994-02-17 Chiron Corporation Endothelin receptor-binding compounds
TW333456B (en) * 1992-12-07 1998-06-11 Takeda Pharm Ind Co Ltd A pharmaceutical composition of sustained-release preparation the invention relates to a pharmaceutical composition of sustained-release preparation which comprises a physiologically active peptide.
CN1049219C (zh) * 1993-08-18 2000-02-09 万有制药株式会社 具有内皮素拮抗活性的芳香杂环并环戊烯衍生物
KR960703901A (ko) * 1993-08-19 1996-08-31 로즈 암스트롱 치환된 2(5H)푸라논, 2(5H)티오페논 및 2(5H)피롤론 유도체, 그의 제조 방법 및 엔도텔린 길항제로서의 그의 용도(Substituted 2(5H)Furanone, 2(5H)Thiophenone and 2(5H)Pyrrolone Derivatives, Their Preparation and Their Use as Endothelin antagonists)
DE4411225A1 (de) * 1994-03-31 1995-10-05 Basf Ag Verwendung von Carbonsäurederivaten als Arzneimittel
EP1186603A3 (en) * 1994-08-19 2003-07-09 Abbott Laboratories Processes for preparing endothelin antagonists
WO1996011927A1 (en) * 1994-10-12 1996-04-25 Abbott Laboratories Endothelin antagonists
DE19533023B4 (de) * 1994-10-14 2007-05-16 Basf Ag Neue Carbonsäurederivate, ihre Herstellung und Verwendung
NZ298853A (en) * 1995-01-27 1998-07-28 Rhone Poulenc Rorer Ltd 5-[2-cyano-phenoxy]-2-phenyl-acetic acid derivatives
CA2168154A1 (en) * 1995-02-06 1996-08-07 Natesan Murugesan Substituted biphenyl sulfonamide endothelin antagonists
DE19614534A1 (de) * 1996-04-12 1997-10-16 Basf Ag Neue Carbonsäurederivate, ihre Herstellung und Verwendung
DE19614542A1 (de) * 1996-04-12 1997-10-16 Basf Ag Neue Carbonsäurederivate, ihre Herstellung und Verwendung
DE19614533A1 (de) * 1996-04-12 1997-10-16 Basf Ag Neue alpha-Hydroxysäurederivate, ihre Herstellung und Verwendung
DE19636046A1 (de) * 1996-09-05 1998-03-12 Basf Ag Neue Carbonsäurederivate, ihre Herstellung und Verwendung als gemischte ET¶A¶/ET¶B¶-Rezeptorantagonisten

Also Published As

Publication number Publication date
SK125299A3 (en) 2001-12-03
AU744019B2 (en) 2002-02-14
JP2001517220A (ja) 2001-10-02
IL131666A0 (en) 2001-01-28
BR9808263A (pt) 2000-05-16
US6030975A (en) 2000-02-29
CA2283732A1 (en) 1998-09-24
NO994426L (no) 1999-11-12
AU734696B2 (en) 2001-06-21
NZ337557A (en) 2001-08-31
HRP980126A2 (en) 1998-12-31
ID24283A (id) 2000-07-13
HUP0002249A2 (hu) 2001-05-28
HUP0002249A3 (en) 2001-11-28
PL335688A1 (en) 2000-05-08
NO994426D0 (no) 1999-09-13
ZA982136B (en) 1999-09-13
CN1251991A (zh) 2000-05-03
EP0969841A1 (en) 2000-01-12
WO1998041206A1 (en) 1998-09-24
KR20000076252A (ko) 2000-12-26

Similar Documents

Publication Publication Date Title
BG103729A (bg) Нови производни на карбоксилни киселини, тяхното получаване и използването им за лечение на рак
AU2000277238A1 (en) Non-mammalian gnrh analogs and uses thereof in tumor cell growth regulation and cancer therapy
EA200001043A3 (ru) Соединения для лечения женской сексуальной дисфункции
UA49787C2 (uk) Спосіб підвищення цитотоксичності хіміотерапевтичного агента та спосіб підвищення цитотоксичності днк-алкілувального хіміотерапевтичного агента
DE69713526D1 (de) Lösliche prodrugs von paclitaxel
GR3034650T3 (en) Substituted dibenzoxazepine compounds, pharmaceutical compositions and methods of use
IL131386A0 (en) Method for the detection and localization of malignant human tumours
MXPA02001571A (es) Metodo de tratamiento para el cancer.
MY121623A (en) Methods of preventing breast cancer.
EP1458734A4 (en) ISOINDIGO, INDIGO AND INDIRUBIN DERIVATIVES AND THEIR USE IN THE TREATMENT OF CANCER
IL136733A0 (en) Pharmaceutical composition containing sibutramine and orlistat
EP1007055A4 (en) METHODS OF ADMINISTERING AMIFOSTINE
NZ511280A (en) Treatment of tumors by administration of growth hormone releasing compounds and their antagonists
EP1419129A4 (en) USE OF BRANCHED CHAIN FATTY ACIDS AND DERIVATIVES THEREOF FOR THE TREATMENT OF PAIN
GR3031114T3 (en) Use of a pregnane derivatives for the treatment of tumours.
KR930700163A (ko) 연조직 종양의 치료 및/또는 진단 방법
YU77002A (sh) Postupak i preparat za tretiranje kancera putem davanja hemoterapeutskog agensa koji indukuje apoptozis
IL140029A0 (en) Radioiodinated phenols for brachytherapy
HK1076601A1 (en) Polypeptide, the conjugate thereof with doxorubicine and a pharmaceutical composition based thereon
CA2069638A1 (en) Mri image enhancement of bone and related tissue using complexes of paramagnetic cations and polyphosphonate ligands
PL344414A1 (en) Combination therapy for the treatment of tumors
GR3030856T3 (en) Use of somatostatin analogues for treating melanomas
RU2004115104A (ru) Расар-композиции и способы визуализации злокачественных опухолей, а также их терапия
EP1011672A4 (en) CONNECTIONS WITH ANALGETIC EFFECT AND COMPILATIONS THAT CONTAIN THEM
AU4918900A (en) Interferon-beta use in the treatment of ewing's family of tumors